Compare UFG & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | PASG |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Singapore | United States |
| Employees | 17 | 27 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 26.0M |
| IPO Year | N/A | 2020 |
| Metric | UFG | PASG |
|---|---|---|
| Price | $0.78 | $5.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 102.5K | ★ 137.8K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.28 |
| 52 Week High | $9.91 | $20.00 |
| Indicator | UFG | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 41.63 |
| Support Level | $0.78 | $3.94 |
| Resistance Level | $1.02 | $7.76 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 5.67 | 63.79 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.